May. 29 at 7:28 PM
Morgan Stanley reiterated
$BHVN Overweight-
$63 and said, "We offer our takeaways from
$BHVN's R&D Day on 5/28."
$TVTX NVS
$AHKSY $SRRK $LLY $RYTM JAZZ IONS
Morgan Stanley added, "Mgmt discussed progress across a diversified pipeline portfolio, presenting new data for degrader platform, and new modalities in oncology and neuroscience.
The company is ramping commercialization efforts ahead of Troriluzole's 4Q PDUFA.
$BHVN highlighted advances across the company's increasingly diversified pipeline portfolio, including in weight/muscle management (anti-myostatin), inflammation/autoimmune (degraders), neurological (ion channels), and oncology (ADCs).
The company presented additional data for immunoglobulin-specific degraders BHV-1400 for IgA nephropathy and BHV-1300 IgG1/2/4 immune-mediated diseases, as well as initial set of data for antibody-drug conjugates (ADCs) for various cancer types.
Morgan Stanley went on to say:
